Journal History
| 2009 | The inaugural issue was released. Cancers was published as a quarterly journal. |
| 2013 | Cancers was indexed in PubMed—National Library of Medicine (NLM), starting with Volume 1 (Issue 1). Cancers was indexed in Scopus (Elsevier), starting with Volume 1 (Issue 1). |
| 2015 | Cancers changed to publish in article number order instead of in page range order. |
| 2016 | Cancers adopted a monthly publication schedule. Cancers announced the first edition of the Travel Awards. The journal Twitter account was established. |
| 2017 | Cancers was indexed in Science Citation Index Expanded (SCIE)—Web of Science (Clarivate Analytics), starting with Volume 9 (Issue 1). |
| 2018 | Cancers received its first Impact Factor (5.326), ranked 44/222 (Q1) in "Oncology". |
| 2019 | Cancers received its 2018 Impact Factor (6.162), ranked 31/229 (Q1) in "Oncology" in JCR. Signal Transduction Society (STS) became affiliated to Cancers. |
| 2020 | Cancers established the following sections: - Molecular Cancer Biology; - Cancer Immunology and Immunotherapy; - Cancer Biomarkers; - Cancer Epidemiology and Prevention; - Cancer Pathophysiology; - Tumor Microenvironment; - Cancer Causes, Screening and Diagnosis; - Cancer Nursing and Care; - Cancer Therapy; - Clinical Trials of Cancer; - Systematic Review or Meta-Analysis in Cancer Research; - Methods and Technologies Development; - Cancer Informatics and Big Data. Cancers announced the first edition of the Outstanding Reviewer Awards and second edition of the Young Investigator Awards. Cancers published its 5,000th paper. Cancers received its 2019 Impact Factor (6.126), ranked 37/244 (Q1) in "Oncology". |
| 2021 | Cancers adopted a semi-monthly publication schedule. Cancers received its 2020 Impact Factor (6.639), ranked 51/242 (Q1) in "Oncology". Cancers published its 10,000th paper. Cancers established the following sections: - Pediatric Oncology; - Infectious Agents and Cancer. Cancers organized the 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response, virtual. |
| 2022 |
- Cancer Nursing and Care was renamed as Transplant Oncology and Cancer Nursing Care. |
| 2023 |
Cancers received its 2022 Impact Factor (5.2), ranked 72/241 (Q2) in "Oncology". |
| 2024 |
Cancers received its 2023 Impact Factor (4.5), ranked 78/322 (Q1) in "Oncology". |
| 2025 |
Cancers received its 2024 Impact Factor (4.4), ranked 85/326 (Q2) in "Oncology". |
| 2026 |
The "North-East German Society for Gynecological Oncology (NOGGO)" became affiliated to Cancers. |
Editor-in-Chief
| 2009–2015 | Editor-in-Chief: Prof. Dr. Robert H. Weiss |
| 2015–present | Editor-in-Chief: Prof. Dr. Samuel C. Mok |
Section Editor-in-Chief
| 2020–2022 | Section Editor-in-Chief: Prof. Dr. Eduardo Nagore for the section on Cancer Epidemiology and Prevention |
| 2020–2023 | Section Editor-in-Chief: Prof. Dr. Fiona Lyng for the section on Methods and Technologies Development |
| 2020–2024 | Section Editor-in-Chief: Prof. Dr. Massoud Mirshahi for the section on Cancer Causes, Screening and Diagnosis |
| 2020–2025 | Section Editor-in-Chief: Dr. Kevin Camphausen for the section on Cancer Therapy Section Editor-in-Chief: Dr. Barbara Wegiel for the section on Cancer Immunology and Immunotherapy |
| 2020–2026 | Section Editor-in-Chief: Prof. Dr. Donat Kögel for the section on Molecular Cancer Biology Section Editor-in-Chief: Prof. Dr. Alexandre Escargueil for the section on Cancer Therapy Section Editor-in-Chief: Prof. Dr. Massimo Di Maio for the section on Systematic Review or Meta-Analysis in Cancer Research |
| 2020–present | Section Editor-in-Chief: Dr. Carlos S. Moreno for the section on Cancer Biomarkers Section Editor-in-Chief: Dr. Nicola Amodio for the section on Cancer Pathophysiology Section Editor-in-Chief: Prof. Dr. Sanjay Gupta for the section on Tumor Microenvironment Section Editor-in-Chief: Dr. Jason Roszik for the section on Cancer Informatics and Big Data |
| 2021–2022 | Section Editor-in-Chief: Prof. Dr. Antoine Italiano for the section on Clinical Trials of Cancer |
| 2022–2023 | Section Editor-in-Chief: Dr. Maen Abdelrahim for the section on Transplant Oncology and Cancer Nursing Care |
| 2022–present | Section Editor-in-Chief: Dr. Sam Mbulaiteye for the section on Infectious Agents and Cancer Section Editor-in-Chief: Prof. Dr. Anupam Bishayee for the section on Cancer Drug Development Section Editor-in-Chief: Prof. Dr. Sanjay K. Srivastava for the section on Cancer Metastasis |
| 2023–2026 | Section Editor-in-Chief: Dr. Farrukh Aqil for the section on Cancer Epidemiology and Prevention Section Editor-in-Chief: Dr. Maen Abdelrahim for the section on Transplant Oncology Section Editor-in-Chief: Prof. Dr. Naoto T. Ueno for the section on Clinical Research in Cancer |
| 2024–present | Section Editor-in-Chief: Prof. Dr. Sebastiano Mercadante for the section on Cancer Survivorship and Quality of Life Section Editor-in-Chief: Prof. Dr. Maxim V. Berezovski for the section on Methods and Technologies Development |
| 2025–present | Section Editor-in-Chief: Prof. Dr. Dawen Zhao for the section on Cancer Causes, Screening and Diagnosis Section Editor-in-Chief: Dr. Massimiliano Berretta for the section on Infectious Agents and Cancer |
| 2026–present | Section Editor-in-Chief: Prof. Dr. Alfred Sze-Lok Cheng for the section on Cancer Immunology and Immunotherapy Section Editor-in-Chief: Dr. Victoria L Seewaldt Cheng for the section on Cancer Epidemiology and Prevention Section Editor-in-Chief: Dr. Dimitrios Moris for the section on Systematic Review or Meta-Analysis in Cancer Research Section Editor-in-Chief: Prof. Dr. James Hicks for the section on Molecular Cancer Biology Section Editor-in-Chief: Prof. Dr. Jörg Kleeff for the section on Clinical Research in Cancer Section Editor-in-Chief: Prof. Dr. Tadeusz Robak for the section on Cancer Therapy |
Cancers - ISSN 2072-6694